A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Corinna Palanca-Wessels, MD, PhD
Seagen Inc.
Study Director - Jorge Ramos, DO
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
176 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Austin Hospital
Heidelberg, Australia
- Cabrini Education and Research Precinct
Malvern, Australia
- Peter Maccallum Cancer Centre
Melbourne, Australia
- Breast Cancer Research Centre
Nedlands, Australia
- Mater Hospital
North Sydney, Australia
- Icon Cancer Care South Brisbane
South Brisbane, Australia
- Mater Health Services
South Brisbane, Australia
- Sunshine Hospital
St Albans, Australia
- Westmead Hospital
Westmead, Australia
- Lkh- Universitat Klinikum Graz
Graz, Austria
- Medizinische Universitat Innsbruck
Innsbruck, Austria
- Kh D. Barmherzigen Schwestern Linz
Linz, Austria
- Lkh Salzburg, Universitatsklinikum Der Pmu
Salzburg, Austria
- Az Klina
Brasschaat, Belgium
- Cliniques Universitaires Saint Luc
Brussels, Belgium
- Grand Hopital de Charleroi
Charleroi, Belgium
- Centre Hospitalier de L'Ardenne
Libramont, Belgium
- Chu Ucl Namur-Site de Saint Elisabeth
Namur, Belgium
- Tom Baker Cancer Centre
Calgary, Canada
- University of Alberta / Cross Cancer Institute
Edmonton, Canada
- Queen Elizabeth Ii Health Sciences Centre
Halifax, Canada
- Jewish General Hospital
Montreal, Canada
- Hopital Du Saint-Sacrement, Chu de Quebec-Universite Laval
Québec, Canada
- Allan Blair Cancer Centre
Regina, Canada
- Saskatoon Cancer Centre
Saskatoon, Canada
- H. Bliss Murphy Cancer Centre
St. John's, Canada
- Sunnybrook Health Sciences Centre
Toronto, Canada
- University Health Network, Princess Margaret Hospital
Toronto, Canada
- British Columbia Cancer Agency - Vancouver Centre
Vancouver, Canada
- Fakultni Nemocnice Hradec Kralove-Oddeleni Klinicke Hematologie
Hradec Králové, Czechia
- Fakultni Nemocnice Olomouc (fnol) - Onkologicka Klinika
Olomouc, Czechia
- Aalborg Universitetshospital
Aalborg, Denmark
- Rigs Hospiltalet
Copenhagen, Denmark
- Herlev Hospital
Herlev, Denmark
- Odense University Hospital
Odense C, Denmark
- Sygehus Lillebaelt - Vejle Sygehus
Vejle, Denmark
- University Hospital of Besancon
Besançon, France
- Clinique Victor Hugo
Le Mans, France
- Centre Leon Berard - Centre Regional de Lutte Contre Le Cancer Rhone-Alpes
Lyon, France
- Institut Paoli Calmettes
Marseille, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Jan 2016
- Primary completion
- 4 Sept 2019
- Completion
- 11 Aug 2022
- Last update posted
- 14 Aug 2023
- Registered enrollment
- 612
- Registry id
- NCT02614794
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.